Introducción
Subcutaneous efgartigimod PH20 (Vyvgart Hytrulo) has shown promising results in the phase III ADAPT OCULUS trial for patients suffering from ocular myasthenia gravis, according to interim data.
Resultados del Estudio
At 4 weeks, patients treated with efgartigimod PH20 exhibited a significant improvement in Myasthenia Impairment Index (MGII) Patient Reported Outcome (PRO) ocular scores compared to those receiving placebo. The mean change from baseline in the efgartigimod group was a 4.04-point increase in the MGII PRO score, versus a 1.99-point increase in the placebo group (mean difference of 2.05 points, P=0.012).
In terms of secondary outcomes, including MGII PRO plus physician examination (MGII PRO+PE) scores, the efgartigimod group showed a mean change of 5.02 points, compared to a 2.57-point change in the placebo group (P=0.018).
Mejoras en Síntomas Claves
Furthermore, efgartigimod significantly improved diplopia (double vision) and ptosis (eyelid drooping). Although the MG-ADL ocular domain scores showed improvements that aligned with the primary MGII PRO ocular endpoint, these changes were not statistically significant (P=0.60).
Dr. Jeff Guptill, a leading researcher at the AANEM’s Myasthenia Gravis Foundation Association, emphasized the importance of patient-reported symptoms in assessing treatment effectiveness.
Detalles del Tratamiento
Efgartigimod is an antibody fragment that targets the neonatal Fc receptor (FcRn) to reduce circulating IgG autoantibodies. Initially approved in 2021 for generalized myasthenia gravis, a subcutaneous formulation with hyaluronidase was introduced in 2023.
The ADAPT OCULUS trial focused on 141 patients with ocular myasthenia gravis, assessing the efficacy and safety of efgartigimod PH20. Most participants were on a stable dose of other treatments, including acetylcholinesterase inhibitors and corticosteroids.
Eventos Adversos
Adverse events recorded were consistent with previous studies involving generalized myasthenia gravis. Common treatment-emergent adverse events included headaches and upper respiratory tract infections.
Conclusiones
Efgartigimod is not yet FDA-approved for ocular myasthenia gravis, but the ADAPT OCULUS trial marks a significant step toward exploring targeted treatments for this condition.
Nota de Descargo de Responsabilidad
La información presentada aquí es solo para fines informativos y educativos. Siempre consulte a un profesional de la salud calificado con cualquier pregunta sobre una condición médica o antes de comenzar un nuevo tratamiento o terapia.
Fuente: https://www.medpagetoday.com/meetingcoverage/aanem/123266
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
